Government-Owned Inventions; Availability for Licensing, 34018-34020 [E7-11824]
Download as PDF
<![CDATA[
34018
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
Dated: June 14, 2007.
Catina Conner,
Acting Assistant Reports Clearance
Officer,Centers for Disease Control and
Prevention.
[FR Doc. E7–11936 Filed 6–19–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Privacy Act of 1974: New System of
Records
Health Resources and Services
Administration (HRSA), HHS.
ACTION: Notification of new system of
records.
AGENCY:
In accordance with the
requirements of the Privacy Act, the
Health Resources and Services
Administration (HRSA) is publishing
notice of a proposal to add a new system
of records titled, ‘‘Information Center
(IC) Integrated Clearinghouse System
(IC/ICS),’’ System No. 09–15–0067. The
HRSA IC/ICS will facilitate the delivery
of publications and requested
information by members of the general
public. The HRSA IC/ICS will also
enable HRSA to deliver information
efficiently through physical mailings or
broadcast e-mail messages to HRSA
Grantee organizations and other
interested parties.
DATES: HRSA invites interested parties
to submit comments on the proposed
New System of Records on or before
July 30, 2007. HRSA has sent a Report
of New Systems of Records to Congress
and to the Office of Management and
Budget (OMB). The New System of
Records will be effective 40 days from
the date submitted to OMB unless
HRSA receives comments which would
result in a contrary determination.
ADDRESSES: Please address comments to
Donn Taylor, Health Resources and
Services Administration, Division of
Management Services, 5600 Fishers
Lane, Room 14A–20, Rockville,
Maryland 20857; Telephone (301) 443–
0204. Comments received will be
available for inspection at this same
address from 9 a.m. to 3 p.m., Monday
through Friday. This is not a toll-free
number.
rwilkins on PROD1PC63 with NOTICES
SUMMARY:
Tina
Cheatham, Acting Director, Office of
Communications, Health Resources and
Services Administration, 5600 Fishers
Lane, Room 14–27, Rockville, Maryland
20857, Telephone: 301–443–3376.
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
Please note this is not a toll free
telephone number.
The
Health Resources and Services
Administration proposes to establish a
new system of records: ‘‘The HRSA
Information Center (IC) Integrated
Clearinghouse System (ICS),’’ HHS/
HRSA/Office of Communications. The
HRSA Information Center provides easy
access to a diversity of resources and a
broad range of health information from
over 70 Agency programs. The HRSA
Information Center makes this
information available to the public,
health care professionals, policy makers
and researchers to enhance their access
to vital knowledge generated by HRSA
supported public health programs.
SUPPLEMENTARY INFORMATION:
Dated: May 31, 2007.
Elizabeth M. Duke,
Administrator.
[FR Doc. 07–3052 Filed 6–19–07; 8:45 am]
BILLING CODE 4165–15–M
Inpatient Hospital Per Diem Rate
(Excludes Physician/Practitioner
Services)
Calendar Year 2007
Lower 48 States: $1,725.
Alaska: $2,208.
Outpatient Per Visit Rate (Excluding
Medicare)
Calendar Year 2007
Lower 48 States: $256.
Alaska: $398.
Outpatient Per Visit Rate (Medicare)
Calendar Year 2007
Lower 48 States: $201.
Alaska: $356.
Medicare Part B Inpatient Ancillary Per
Diem Rate
Calendar Year 2007
Lower 48 States: $353.
Alaska: $613.
Outpatient Surgery Rate (Medicare)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Established Medicare rates for
freestanding Ambulatory Surgery
Centers
Indian Health Service
Effective Date for Calendar Year 2007
Rates
Reimbursement Rates for Calendar
Year 2007
Consistent with previous annual rate
revisions, the Calendar Year 2007 rates
will be effective for services provided
on/or after January 1, 2007 to the extent
consistent with payment authorities
including the applicable Medicaid State
plan.
AGENCY:
ACTION:
Indian Health Service, HHS.
Notice.
SUMMARY: Notice is given that the
Director of Indian Health Service (IHS),
under the authority of sections 321(a)
and 322(b) of the Public Health Service
Act (42 U.S.C. 248 and 249(b)), Public
Law 83–568 (42 U.S.C. 2001(a)), and the
Indian Health Care Improvement Act
(25 U.S.C. 1601 et seq.), has approved
the following rates for inpatient and
outpatient medical care provided by IHS
facilities for Calendar Year 2007 for
Medicare and Medicaid beneficiaries
and beneficiaries of other Federal
programs. The Medicare Part A
inpatient rates are excluded from the
table below as they are paid based on
the prospective payment system. Since
the inpatient rates set forth below do not
include all physician services and
practitioner services, additional
payment may be available to the extent
that those services meet applicable
requirements. Public Law 106–554,
section 432, dated December 21, 2000,
authorized IHS facilities to file Medicare
Part B claims with the carrier for
payment for physician and certain other
practitioner services provided on or
after July 1, 2001.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Dated: January 4, 2007.
Charles W. Grim,
Assistant Surgeon General, Director, Indian
Health Service.
[FR Doc. 07–3037 Filed 6–19–07; 8:45 am]
BILLING CODE 4165–16–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
E:\FR\FM\20JNN1.SGM
20JNN1
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Synthetic Macrolides Inhibit Breast
Cancer Migration
Description of Technology: This
technology relates to the synthesis of
several novel macrocylic compounds
(macrolides), built upon a quinic acidcontaining scaffold, which are potent
inhibitors of tumor cell migration.
Specifically, the new molecules have
been shown to inhibit breast cancer cell
migration in vitro.
Tumor metastasis or cell migration is
a multi-step process in which primary
tumor cells spread or migrate by
invading adjacent tissues and/or
metastasizing to distance sites. Thus,
one approach to cancer treatment may
be the inhibition of tumor migration.
The initial observation that migrastatin,
a macrolide natural product first
isolated from a Streptomycete, inhibits
tumor cell migration gave rise to the
synthesis of the analogs with increased
potency and tumor cell selectivity
reported here.
Applications: These compounds may
be the basis for new antimetastatic and
antiangiogenic drugs. Some of the novel
macrolides that have been designed and
synthesized, inhibit tumor cell
migration with low nanomolar to submicromolar IC50 values via a mechanism
that appears to be similar to that of
migrastatin and its analogs. The
synthetic protocol used is straight
forward and relatively high yielding,
and has the potential to be further
simplified.
The new compounds and methods
may be used to treat a pathologic
condition that may be ameliorated by
inhibiting or decreasing cell migration
or metastasis, to decrease anchoragedependent growth of tumor cells, or to
treat any pathologic condition
characterized by neovascularization.
Advantages: The new molecules have
been shown to inhibit breast cancer cell
migration in vitro. Breast cancer is the
most common female cancer in the
United States, the second most common
cause of death in women and the main
cause of death in women ages 45 to 55.
VerDate Aug<31>2005
19:44 Jun 19, 2007
Jkt 211001
Despite early diagnosis and treatment,
recurrence of the cancer including
distant tumor growth or metastases is
common. Accordingly, there is a need
for compounds, such as those described
in this invention, that inhibit cell
migration and angiogenesis.
Development Status: Synthesis of
several analogs has been carried out;
Migration of breast cancer cells has been
demonstrated to be inhibited in vitro at
sub-micromolar IC50 values; The lead
compound has been demonstrated not
to be cytotoxic at levels up to 100
micromolar; Scaled up synthesis of the
most potent macrolide is presently
being scaled up to unable for future
testing in a mouse model of breast
cancer.
Inventors: Dr. Carole Bewley (NIDDK),
Dr. Belhu B. Metaferia (NIDDK).
Publication: BB Metaferia, L Chen, HL
Baker, XY Huang, CA Bewley. Synthetic
macrolides that inhibit breast cancer
cell migration in vitro. J Am Chem Soc.
2007 Mar 7;129(9):2434–2435. Epub
2007 Feb 13, doi 10.1021/ja068538d.
Patent Status: U.S. Provisional
Application No. 60/900,151 filed 07 Feb
2007 (HHS Reference No. E–098–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Michelle Booden,
Ph.D.; 301/451–7337;
boodenm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases,
Laboratory of Bioorganic Chemistry, is
seeking parties interested in
collaborative research to develop larger
scale syntheses of the most potent
macrolides and/or analogs thereof, and
the conduct toxicology and other
efficacy studies related to these
macrolides. Please contact Dr. Carole
Bewley at caroleb@mail.nih.gov or
Rochelle S. Blaustein at
Rochelle.Blaustein@nih.gov for more
information.
Immunotoxin With In-Vivo T Cell
Suppressant Activity
Description of Invention: The
invention concerns immunotoxins and
methods of using the immunotoxins for
the treatment of autoimmune diseases
and T cell malignancies. The
immunotoxins are targeted via an
antibody that is specific to T cells. This
allows the specific ablation of malignant
T cells and resting T cells. The transient
ablation of resting T cells can ‘‘reset’’
the immune system by accentuating
tolerizing responses. The toxin portion
of the immunotoxin is genetically
engineered to maintain bioactivity when
recombinantly produced in Pichia
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
34019
pastoris. Data are available in transgenic
animals expressing human CD3e which
supports the effects of the immunotoxin
against T cells.
Applications: Treatment of
autoimmune diseases such as multiple
sclerosis, lupus, type I diabetes, aplastic
anemia; Treatment of T cell leukemias
and lymphomas such as cutaneous T
cell leukemia/lymphoma (CTCL).
Advantages: Specificity of the
immunotoxin avoids the killing of nonT cells, reducing side-effects associated
with other mechanisms of treatment
(e.g., radiation and cyclophosphamide)
such as infection and induced
malignancy; A GMP production process
has already been successfully
implemented, and patient doses are
available; All testing required for an
FDA issued IND has been completed,
allowing faster evaluation of the efficacy
of the invention.
Benefits: New methods and
compositions with limited side-effects
have the potential to revolutionize
treatment of autoimmune disease;
provides an opportunity to capture a
significant market share for the millions
of people who suffer from an
autoimmune disease.
Inventors: David Neville et al.
(NIMH).
Patent Status: U.S. Patent No.
5,167,956 issued 01 Dec 1992 (HHS
Reference No. E–012–1991/0–US–01);
U.S. Patent No. 5,725,857 issued 10 Mar
1998 (HHS Reference No. E–012–1991/
2–US–01); U.S. Patent No. 6,632,928
issued 14 Oct 2003 (HHS Reference No.
E–044–1997/0–US–07); U.S. Patent
Application No. 10/435,567 filed 09
May 2003, which published as 2003/
0185825 on 02 Oct 2003 (HHS Reference
No. E–044–1997/0–US–08); U.S. Patent
Application No. 10/296,085 filed 18
Nov 2002, which published as 2004/
0127682 on 01 Jul 2004 (HHS Reference
No. E–044–1997/1–US–06); Foreign
rights are also available
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: David A.
Lambertson, Ph.D.; 301/435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health,
Laboratory of Molecular Biology, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
methods of using the immunotoxins for
the treatment of autoimmune diseases
and T cell malignancies. Please contact
David Neville at davidn@mail.nih.gov
for more information.
E:\FR\FM\20JNN1.SGM
20JNN1
34020
Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices
Dated: June 13, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer,Office of Technology
Transfer,National Institutes of Health.
[FR Doc. E7–11824 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
rwilkins on PROD1PC63 with NOTICES
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
NUP98–HOXD13 Transgenic Mice
Description of Technology:
Myelodysplastic syndrome (MDS) is
collection of closely related blood
diseases that arise in the bone marrow
characterized by anemia, neutropenia,
and thrombocytopenia resulting from
hematopoietic stem cell disorders. A
variety of genetic aberrations have been
associated with MDS, including
chromosomal translocations of the
NUP98 gene. The only current curative
therapy for MDS is allogeneic bone
marrow transplant. Without bone
marrow transplant, patients either die of
progressive pancytopenia or following
transformation of MDS to acute myeloid
leukemia. Progress in understanding
and treating MDS has been hampered by
a lack of an animal model that
accurately recapitulates all of the
features of human MDS. Utilizing a
NUP98-HOXD13 (hereafter NHD13)
fusion gene, a mouse model was
VerDate Aug<31>2005
18:25 Jun 19, 2007
Jkt 211001
developed to elucidate the biology of
MDS. Genetically engineered mice that
express an NHD13 transgene display all
of the phenotypic features of MDS
including peripheral blood cytopenia,
bone marrow dysplasia, and
transformation to acute leukemia. These
mice provide an accurate preclinical
model for MDS.
Applications: Model to study MDS
and evaluate MDS therapy.
Market: 15,000–20,000 new cases of
MDS are diagnosed in the U.S.; 80–90%
of patients are older than 60 years old.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Peter D. Aplan et al. (NCI).
Publications:
1. YW Lin et al. Notch1 mutations are
important for leukemic transformation
in murine models of precursor-T
leukemia/lymphoma. Blood. 2006 Mar
15;107(6):2540–2543.
2. YW Lin et al., NUP98-HOXD13
transgenic mice develop a highly
penetrant, severe myelodysplastic
syndrome that progresses to acute
leukemia. Blood. 2005 Jul 1;106(1):287–
295.
Patent Status: HHS Reference No. E–
071–2007/0—Research Tool.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Leukemia Biology Section, Genetics
Branch, National Cancer Institute is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
NHD13 mouse model. Please contact
John D. Hewes, Ph.D. at 301–435–3121
or hewesj@mail.nih.gov for more
information.
Identification of Ovarian Cancer Tumor
Markers and Therapeutic Agents
Description of Technology: Germline
mutations of BRCA1 and BRCA2 tumor
suppressor genes are responsible for
5%–10% of all epithelial ovarian
cancers. However, little is known about
the molecular mechanisms involved in
BRCA1 and/or BRCA2 mutationassociated (termed BRCA-linked)
ovarian carcinogenesis. To elucidate
their pathways, microarrays were used
to compare gene expression patterns in
ovarian cancers associated with BRCA1
or BRCA2 mutations with gene
expression patterns in sporadic
epithelial ovarian cancers to identify
patterns common to both hereditary and
sporadic tumors. As a result of this
analysis, genes that are upregulated in
ovarian cancer were identified.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Approximately two-thirds of the
sequences identified were previously
known genes, while approximately onethird were expressed sequence tags,
representing sequences that are cloned
and identified but not yet characterized.
Eighty-three genes were over-expressed
in 50% of all tumors and these overexpressed sequences may be used as
markers for ovarian cancer and/or
targets for therapy.
Applications: Method to diagnose
ovarian cancer; Method to treat ovarian
cancer with therapeutics that target
ovarian biomarkers; Ovarian cancer
therapeutics that inhibit ovarian cancer
markers such as siRNA.
Market: Estimated 180,000 new cases
of breast cancer in the U.S. in 2007;
Estimated 41,000 deaths due to breast
cancer in the U.S. in 2007.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Amir Jazaeri (NCI), Edison
T. Liu (NCI), et al.
Publications:
1. AA Jazaeri et al. BRCA1-mediated
repression of select X chromosome
genes. J Transl Med. 2004 Sep
21;2(1):32.
2. AA Jazaeri et al. Molecular
determinants of tumor differentiation in
papillary serous ovarian carcinoma. Mol
Carcinog. 2003 Feb;36(2):53–59.
3. AA Jazaeri et al. Gene expression
profiles of BRCA1-linked, BRCA2linked, and sporadic ovarian cancers. J
Natl Cancer Inst. 2002 Jul 3;94(13):990–
1000.
Patent Status: U.S. Provisional
Application No. 60/357,031 filed 13 Feb
2002 (HHS Reference No. E–310–2001/
0–US–01); PCT Patent Application No.
PCT/US2003/046888 filed 13 Feb 2003
(HHS Reference No. E–310–2001/0–
PCT–02); U.S. Patent Application No.
10/505,680 filed 12 Aug 2004 (HHS
Reference No. E–310–2001/0–US–03).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301/435–4633; wongje@mail.nih.gov.
Tumor Markers in Ovarian Cancer
Description of Technology: Ovarian
cancer is one of the most common forms
of neoplasia in women. Although
advanced ovarian cancer has only a 20–
30% survival rate, an estimated 90% of
cases are effectively treated when
detected early. However, few symptoms
are associated with early ovarian cancer,
and approximately 25% of ovarian
cancer cases are diagnosed before it
metastasizes. Utilizing SAGE analysis, a
unique set of ovarian cancer biomarkers
has been identified that are highly
expressed in ovarian epithelial tumor
E:\FR\FM\20JNN1.SGM
20JNN1
]]>Agencies
[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Pages 34018-34020]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11824]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected
[[Page 34019]]
inventions to extend market coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Synthetic Macrolides Inhibit Breast Cancer Migration
Description of Technology: This technology relates to the synthesis
of several novel macrocylic compounds (macrolides), built upon a quinic
acid-containing scaffold, which are potent inhibitors of tumor cell
migration. Specifically, the new molecules have been shown to inhibit
breast cancer cell migration in vitro.
Tumor metastasis or cell migration is a multi-step process in which
primary tumor cells spread or migrate by invading adjacent tissues and/
or metastasizing to distance sites. Thus, one approach to cancer
treatment may be the inhibition of tumor migration. The initial
observation that migrastatin, a macrolide natural product first
isolated from a Streptomycete, inhibits tumor cell migration gave rise
to the synthesis of the analogs with increased potency and tumor cell
selectivity reported here.
Applications: These compounds may be the basis for new
antimetastatic and antiangiogenic drugs. Some of the novel macrolides
that have been designed and synthesized, inhibit tumor cell migration
with low nanomolar to sub-micromolar IC50 values via a
mechanism that appears to be similar to that of migrastatin and its
analogs. The synthetic protocol used is straight forward and relatively
high yielding, and has the potential to be further simplified.
The new compounds and methods may be used to treat a pathologic
condition that may be ameliorated by inhibiting or decreasing cell
migration or metastasis, to decrease anchorage-dependent growth of
tumor cells, or to treat any pathologic condition characterized by
neovascularization.
Advantages: The new molecules have been shown to inhibit breast
cancer cell migration in vitro. Breast cancer is the most common female
cancer in the United States, the second most common cause of death in
women and the main cause of death in women ages 45 to 55. Despite early
diagnosis and treatment, recurrence of the cancer including distant
tumor growth or metastases is common. Accordingly, there is a need for
compounds, such as those described in this invention, that inhibit cell
migration and angiogenesis.
Development Status: Synthesis of several analogs has been carried
out; Migration of breast cancer cells has been demonstrated to be
inhibited in vitro at sub-micromolar IC50 values; The lead
compound has been demonstrated not to be cytotoxic at levels up to 100
micromolar; Scaled up synthesis of the most potent macrolide is
presently being scaled up to unable for future testing in a mouse model
of breast cancer.
Inventors: Dr. Carole Bewley (NIDDK), Dr. Belhu B. Metaferia
(NIDDK).
Publication: BB Metaferia, L Chen, HL Baker, XY Huang, CA Bewley.
Synthetic macrolides that inhibit breast cancer cell migration in
vitro. J Am Chem Soc. 2007 Mar 7;129(9):2434-2435. Epub 2007 Feb 13,
doi 10.1021/ja068538d.
Patent Status: U.S. Provisional Application No. 60/900,151 filed 07
Feb 2007 (HHS Reference No. E-098-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Michelle Booden, Ph.D.; 301/451-7337;
boodenm@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic
Chemistry, is seeking parties interested in collaborative research to
develop larger scale syntheses of the most potent macrolides and/or
analogs thereof, and the conduct toxicology and other efficacy studies
related to these macrolides. Please contact Dr. Carole Bewley at
caroleb@mail.nih.gov or Rochelle S. Blaustein at
Rochelle.Blaustein@nih.gov for more information.
Immunotoxin With In-Vivo T Cell Suppressant Activity
Description of Invention: The invention concerns immunotoxins and
methods of using the immunotoxins for the treatment of autoimmune
diseases and T cell malignancies. The immunotoxins are targeted via an
antibody that is specific to T cells. This allows the specific ablation
of malignant T cells and resting T cells. The transient ablation of
resting T cells can ``reset'' the immune system by accentuating
tolerizing responses. The toxin portion of the immunotoxin is
genetically engineered to maintain bioactivity when recombinantly
produced in Pichia pastoris. Data are available in transgenic animals
expressing human CD3[epsi] which supports the effects of the
immunotoxin against T cells.
Applications: Treatment of autoimmune diseases such as multiple
sclerosis, lupus, type I diabetes, aplastic anemia; Treatment of T cell
leukemias and lymphomas such as cutaneous T cell leukemia/lymphoma
(CTCL).
Advantages: Specificity of the immunotoxin avoids the killing of
non-T cells, reducing side-effects associated with other mechanisms of
treatment (e.g., radiation and cyclophosphamide) such as infection and
induced malignancy; A GMP production process has already been
successfully implemented, and patient doses are available; All testing
required for an FDA issued IND has been completed, allowing faster
evaluation of the efficacy of the invention.
Benefits: New methods and compositions with limited side-effects
have the potential to revolutionize treatment of autoimmune disease;
provides an opportunity to capture a significant market share for the
millions of people who suffer from an autoimmune disease.
Inventors: David Neville et al. (NIMH).
Patent Status: U.S. Patent No. 5,167,956 issued 01 Dec 1992 (HHS
Reference No. E-012-1991/0-US-01); U.S. Patent No. 5,725,857 issued 10
Mar 1998 (HHS Reference No. E-012-1991/2-US-01); U.S. Patent No.
6,632,928 issued 14 Oct 2003 (HHS Reference No. E-044-1997/0-US-07);
U.S. Patent Application No. 10/435,567 filed 09 May 2003, which
published as 2003/0185825 on 02 Oct 2003 (HHS Reference No. E-044-1997/
0-US-08); U.S. Patent Application No. 10/296,085 filed 18 Nov 2002,
which published as 2004/0127682 on 01 Jul 2004 (HHS Reference No. E-
044-1997/1-US-06); Foreign rights are also available
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: David A. Lambertson, Ph.D.; 301/435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Mental Health, Laboratory of Molecular Biology, is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize methods of
using the immunotoxins for the treatment of autoimmune diseases and T
cell malignancies. Please contact David Neville at davidn@mail.nih.gov
for more information.
[[Page 34020]]
Dated: June 13, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer,Office of
Technology Transfer,National Institutes of Health.
[FR Doc. E7-11824 Filed 6-19-07; 8:45 am]
BILLING CODE 4140-01-P
